Literature DB >> 827034

Dexamethasone and DMSO in experimental transorbital cerebral infarction.

J C de la Torre, J W Surgeon.   

Abstract

Twenty rhesus monkeys were used to evaluate the effects of dexamethasone and dimethyl sulfoxide (DMSO) following experimental occlusion of the middle cerebral artery (MCA) for 17 hours. Animals were initially treated after four hours while the MCA remained occluded and a series of tests was used to evaluate the neurological and cerebral status of each monkey for seven days. The results show that the gross, microscopic and angiographical picture of dexamethasone and no-treatment controls was practically identical. In contrast, DMSO-treated monkeys showed significant protection from the severe neurological deficits seen in the other groups. It is concluded that DMSO has a positive effect in reducing the neurological deficits seen in this model and may be potentially useful in clinical emoblic stroke.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 827034     DOI: 10.1161/01.str.7.6.577

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  An intravascular technique to occlude the middle cerebral artery in baboons.

Authors:  F Brassel; C Dettmers; A Nierhaus; A Hartmann; L Solymosi
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

2.  Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model.

Authors:  Juergen Bardutzky; Xianjun Meng; James Bouley; Timothy Q Duong; Rajiv Ratan; Marc Fisher
Journal:  J Cereb Blood Flow Metab       Date:  2005-08       Impact factor: 6.200

3.  The response of focal ischemic cerebral edema to dexamethasone.

Authors:  A Fenske; M Fischer; F Regli; U Hase
Journal:  J Neurol       Date:  1979-05-02       Impact factor: 4.849

4.  Comparison of the effects of DMSO and pentobarbitone on experimental brain oedema.

Authors:  H E James; P E Camp; R D Harbaugh; L F Marshall; R Werner
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.